Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025

4 days ago 3

Adé Hennis, The Motley Fool

Wed, January 14, 2026 astatine 4:23 AM CST 4 min read

On Dec. 8, 2025, the Executive Vice President and Chief Commercial Officer of Collegium Pharmaceutical sold 17,600 shares straight done an workout of options.
The merchantability represented 14.5% of Dreyer's nonstop holdings astatine the time, reducing his nonstop ownership to 103,613 shares.
COLL shares surged astir 60% successful 2025, reaching an all-time precocious successful the past week of December.
These 10 stocks could mint the adjacent question of millionaires ›

On Dec. 8, 2025, Scott Dreyer, EVP & CCO of Collegium Pharmaceutical (NASDAQ:COLL), exercised options and instantly sold 17,600 communal shares successful a derivative transaction for a full worth of ~$847,800, arsenic disclosed successful a SEC Form 4 filing.

Metric

Value

Shares sold (direct)	17,600
Transaction value	~$847,800
Post-transaction shares (direct)	103,613
Post-transaction worth (direct ownership)	~$5.04 million

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($48.17); post-transaction worth based connected the banal terms connected the adjacent of Dec. 8, 2025 ($48.66).

How did the transactions impact the insiders' nonstop holdings?
This resulted successful a zero nett summation successful ownership, arsenic each 17,600 shares from Dreyer's enactment workout were instantly sold.
How does the size of this merchantability comparison to Dreyer's humanities selling patterns?
The 17,600-share merchantability is supra the caller median of 15,387 shares per merchantability trade.
Was this enactment conducted nether a trading program oregon astatine the insider's discretion?
The transaction was carried retired pursuant to a Rule 10b5-1 trading program adopted connected Sept. 3, 2025, which indicates the timing was prearranged alternatively than discretionary.

Metric

Value

Market capitalization	$1.49 billion
Employees	357
Revenue (TTM)	$757.07 million
Net income (TTM)	$58.4 million
Headquarters	Stoughton, MA

Collegium Pharmaceutical is simply a healthcare institution specializing successful innovative solutions for symptom absorption and assorted wellness conditions.
One of the company's biggest pharmaceutical products wrong its portfolio is simply a medicine medicine that serves arsenic attraction for attraction shortage hyperactivity upset (ADHD).

Because Dreyer's merchantability of shares was pre-set nether a 10b5-1 trading plan, the transactions don't transportation meaningful value from an concern investigation standpoint. And the exercised options were the past insider transactions filed for 2025.

Collegium had beardown financials and banal show successful 2025 and is looking to thrust that momentum passim 2026. The banal roseate 59% past twelvemonth and reached an all-time precocious of 50.79 connected Dec. 29. And successful a fiscal guidance and concern update that was published connected Jan. 8, the institution predicts that the important occurrence of its portfolio of ADHD and symptom pharmaceuticals volition proceed passim the year.